PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
The rising prevalence of cancer and demand for targeted therapies are fueling market expansion. Additionally, advancements in clinical trials and rising collaborations between pharmaceutical companies are further propelling the market forward. LAS VEGAS Oct. 1, 2024 /PRNewswire/ -- DelveInsight's PLK-1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PLK-1 inhibitors, market share of individual therapies, and current and forecasted PLK-1 inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany France Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the PLK-1 Inhibitors Market Report As per DelveInsight's analysis, the total market size of PLK-1 inhibitors in the 7MM is expected to surge significantly by 2034. Leading PLK-1 inhibitor companies such as Cardiff Oncology, Notable Labs, Cyclacel Pharmaceuticals, and others are developing novel PLK-1
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]Yahoo! Finance
- CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/7/24 - Beat
CRDF
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form SCHEDULE
- 12/16/24 - Form 4
- CRDF's page on the SEC website